Keywords: Biosimilars, Biological markets, URCH, Forecasts

Biosimilars could account for 2.6% of biological market by 2016, forecasts URCH

Article | 30 March 2010

The value of the biosimilars market segment will account for 2.6% of the biological market by 2016, forecasts a new report from URCH Publishing. However, this forecast assumes biosimilars become permitted under US law by 2012, notes the market strategy report “Biosimilars: A Growing Market - An overview of developments, companies and commercial opportunities.”

The biosimilars market segment is poorly developed but is widely expected to become a significant commercial segment over the next few years, capturing a healthy percentage share of the biologicals market. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in